trial · primary record
Secutrelvir
SARS-CoV-2
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 2000 |
| Primary completion | 2028-12-31 |
| Primary endpoint | Proportion of Participants Experiencing Any Component of the Following Composite Endpoint: Targeted Medically Attended Visits (tMAVs) Due to Worsening COVID-19, All-cause Hospitalizations, or All-cause Deaths |
| Registry ID | NCT07743580 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:52.149Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07743580
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.